The pharmacokinetics of cefepime were studied in 10 male patients receiving continuous ambulatory peritoneal dialysis therapy. Five patients received a single 1,000-mg dose and the other five received a single 2,000-mg dose; all doses were given as 30-min intravenous infusions. Serial plasma, urine, and peritoneal dialysate samples were collected; and the concentrations of cefepime in these fluids were measured over 72 h by using a high-performance liquid chromatographic assay with UV detection. Pharmacokinetic parameters were calculated by noncompartmental methods. The peak concentrations in plasma and the areas under the plasma concentration-versus-time curve for the 2,000-mg dose group were twice as high as those observed for the 1,000-mg dose group. The elimination half-life of cefepime was about 18 h and was independent of the dose. The steady-state volume of distribution was about 22 liters, and values for the 1,000-and 2,000-mg doses were not significantly different. The values for total body clearance and peritoneal dialysis clearance were about 15 and 4 ml/min, respectively. No dose dependency was observed for the clearance estimates. Over the 72-h sampling period, about 26% of the dose was excreted intact into the peritoneal dialysis fluid. For 48 h postdose, mean concentrations of cefepime in dialysate at the end of each dialysis interval exceeded the reported MICs for 90%o of bacteria which commonly cause peritonitis resulting from continuous peritoneal dialysis. A
not significantly different. The values for total body clearance and peritoneal dialysis clearance were about 15 and 4 ml/min, respectively. No dose dependency was observed for the clearance estimates. Over the 72-h sampling period, about 26% of the dose was excreted intact into the peritoneal dialysis fluid. For 48 h postdose, mean concentrations of cefepime in dialysate at the end of each dialysis interval exceeded the reported MICs for 90%o of bacteria which commonly cause peritonitis resulting from continuous peritoneal dialysis. A parenteral dose of 1,000 or 2,000 mg of cefepime every 48 h would maintain the antibiotic levels in plasma and peritoneal fluid above the MICs for 90% of the most susceptible bacteria for the treatment of systemic and intraperitoneal infections.
Cefepime (BMY-28142) is a new parenteral cephalosporin antibiotic with a broad antibacterial spectrum (7, 13) and a low affinity for chromosomally mediated j3-lactamases (17, 22) . Clinical experience indicates that cefepime is safe and well tolerated. The pharmacokinetic properties of cefepime are well documented (1, 2, (4) (5) (6) . In normal male subjects, cefepime has a mean elimination half-life (t1l2) of about 2.2 h and obeys linear kinetics over an intravenous dose range of 250 to 2,000 mg (1, 2) . Over 85% of the administered dose is recovered in urine as intact cefepime in subjects with normal kidney function (5) . The safety, tolerance, and pharmacokinetics of cefepime have been evaluated in patients with renal impairment, including those on hemodialysis, and dosing regimen adjustments have been developed (4) .
Continuous ambulatory peritoneal dialysis (CAPD) is a self-dialysis procedure which is widely recommended as an alternative to hemodialysis in the treatment of end-stage renal disease (15, 18) . However, peritonitis is a major and often serious complication of CAPD. Approximately 60% of patients undergoing CAPD develop peritonitis within the first year of the initiation of dialysis (16) . Bacterial peritonitis is generally caused by catheter contamination by common skin organisms. The antibacterial spectrum of cefepime covers the bacteria known to cause CAPD-induced peritonitis (16, 21 p,g/ml were 9, 9, and 7.4%, respectively, where n is the number of replicates of the quality-control sample. The between-day coefficients of variation for quality-control samples of cefepime in urine at concentrations of 10 (n = 3), 500 (n = 3), and 1,000 (n = 3) ,ug/ml were 4. Pharmacokinetics. Mean plasma cefepime concentrationversus-time profiles following administration of the 1,000-and 2,000-mg doses are shown in Fig. 1 . The penetration of cefepime into the peritoneal cavity was rapid. The average concentrations of cefepime were 8.8 and 16.5 ,ug/ml 1 h after administration of the 1,000-and 2,000-mg doses, respectively. The maximum concentrations of cefepime in peritoneal dialysate, 27.0 and 60.7 ,ug/ml, were observed 6 h after intravenous administration of the 1,000-and 2,000-mg doses, respectively (Fig. 2) . Over the 72-h observation period, about 25% of the administered dose was excreted into the peritoneal dialysis fluid. Less than 5% of the dose was recovered in urine as intact cefepime.
Pharmacokinetic data for individual patients and their mean values by dose group are given in Table 1 . The values for Cmax, and AUC for the 2,000-mg dose group were twice as high as those observed in the 1,000-mg dose group. Tle t1/2 of cefepime was about 18 h in patients undergoing CAPD and was independent of the dose. The V.., of cefepime was about (1, 2) and various degrees of renal insufficiency (4, 5) . The data that we obtained in the present study support and extend the findings of the previous studies, namely, that renal impairment does not affect the distribution of cefepime in the body.
As a route of elimination of systemically administered cefepime, CAPD appears to be a less efficient process than hemodialysis. The CLD of cefepime in the present study was about 9% of that reported for patients on hemodialysis (4). If it were necessary to remove cefepime from the body as rapidly as possible, as in the case of overdosage, hemodialysis should be used.
The CLD of cefepime (about 4 ml/min) is higher than those reported for ceftizoxime (3 By using the mean values for CL in patients undergoing CAPD (14.7 ml/min) and individuals with normal renal function (130 ml/min) and an 8-h dosing interval in patients with normal kidney function, a dosing interval of 70.7 h is calculated for patients undergoing CAPD. This calculation is supported by the observation that, for the 1,000-mg dose, the cefepime levels in plasma at 72 h in patients undergoing CAPD in the present study and at 8 h in individuals with normal renal function (2) are similar. Therefore, for the treatment of systemic infections in patients undergoing CAPD, a cefepime dosage once every 72 h at a 1,000-or 2,000-mg dose level would maintain levels of drug in blood equivalent to those with dosing once every 8 h in patients with normal renal function.
The present study was carried out in patients undergoing CAPD but who did not have peritonitis. Peritoneal transfer of some antibiotics (12) and some endogenous substances such as urea and creatinine (20) may be altered in the presence of inflamed peritoneal membranes during peritonitis. The clinical relevance of a possible alteration in the pharmacokinetics of cefepime, a cephalosporin with a wide therapeutic margin, in patients with peritonitis undergoing CAPD is questionable. However, further studies of cefepime in patients with and without documented peritonitis undergoing CAPD may be necessary to characterize the effects of peritonitis on the pharmacokinetics of cefepime following an intraperitoneal dose.
Results of the present study suggest that cefepime is safe and well tolerated in patients undergoing CAPD. A parenteral dose of 1,000 or 2,000 mg every 48 h would maintain therapeutic levels of cefepime in plasma and peritoneal fluid for the treatment of systemic and intraperitoneal infections caused by susceptible bacteria, but it would not cause an excessive accumulation of the cephalosporin.
